264 related articles for article (PubMed ID: 11574546)
1. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C.
Okuda H; Saitoh K; Hirai S; Iwai K; Takaki Y; Baba M; Minato N; Ohno S; Shuin T
J Biol Chem; 2001 Nov; 276(47):43611-7. PubMed ID: 11574546
[TBL] [Abstract][Full Text] [Related]
2. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
3. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
[TBL] [Abstract][Full Text] [Related]
4. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
[TBL] [Abstract][Full Text] [Related]
5. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
Pioli PA; Rigby WF
J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
Li Z; Na X; Wang D; Schoen SR; Messing EM; Wu G
J Biol Chem; 2002 Feb; 277(7):4656-62. PubMed ID: 11739384
[TBL] [Abstract][Full Text] [Related]
7. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
8. pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion.
Kanaya K; Kamitani T
Biochem Biophys Res Commun; 2003 Jul; 306(3):750-5. PubMed ID: 12810083
[TBL] [Abstract][Full Text] [Related]
9. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
Corn PG; McDonald ER; Herman JG; El-Deiry WS
Nat Genet; 2003 Nov; 35(3):229-37. PubMed ID: 14556007
[TBL] [Abstract][Full Text] [Related]
10. The COP9/signalosome increases the efficiency of von Hippel-Lindau protein ubiquitin ligase-mediated hypoxia-inducible factor-alpha ubiquitination.
Miyauchi Y; Kato M; Tokunaga F; Iwai K
J Biol Chem; 2008 Jun; 283(24):16622-31. PubMed ID: 18424433
[TBL] [Abstract][Full Text] [Related]
11. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
Biochem Biophys Res Commun; 2002 Jun; 294(3):700-9. PubMed ID: 12056827
[TBL] [Abstract][Full Text] [Related]
12. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.
Schoenfeld AR; Davidowitz EJ; Burk RD
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8507-12. PubMed ID: 10900011
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
[TBL] [Abstract][Full Text] [Related]
14. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
15. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
Lonergan KM; Iliopoulos O; Ohh M; Kamura T; Conaway RC; Conaway JW; Kaelin WG
Mol Cell Biol; 1998 Feb; 18(2):732-41. PubMed ID: 9447969
[TBL] [Abstract][Full Text] [Related]
16. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
17. The von Hippel-Lindau tumour suppressor protein: new perspectives.
Ohh M; Kaelin WG
Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821
[TBL] [Abstract][Full Text] [Related]
18. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein.
Groulx I; Lee S
Mol Cell Biol; 2002 Aug; 22(15):5319-36. PubMed ID: 12101228
[TBL] [Abstract][Full Text] [Related]
19. The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta.
Iturrioz X; Durgan J; Calleja V; Larijani B; Okuda H; Whelan R; Parker PJ
Biochem J; 2006 Jul; 397(1):109-20. PubMed ID: 16669786
[TBL] [Abstract][Full Text] [Related]
20. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase.
Kamura T; Brower CS; Conaway RC; Conaway JW
J Biol Chem; 2002 Aug; 277(33):30388-93. PubMed ID: 12048197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]